- Trials with a EudraCT protocol (153)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
153 result(s) found for: Tenofovir disoproxil fumarate.
Displaying page 4 of 8.
EudraCT Number: 2017-001518-27 | Sponsor Protocol Number: MK-1439-027 | Start Date*: 2018-02-27 | |||||||||||
Sponsor Name:NIAID, NICHD, NIMH | |||||||||||||
Full Title: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescen... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001193-34 | Sponsor Protocol Number: STRIB-PEP | Start Date*: 2014-07-16 | |||||||||||
Sponsor Name:Fundació Clínic per a la recerca biomèdica | |||||||||||||
Full Title: COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICIS... | |||||||||||||
Medical condition: Prophilaxis VIH infecction post accidental exposition (PPE) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003345-29 | Sponsor Protocol Number: 3568 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Kings College Hospital NHS Foundation Trust | |||||||||||||
Full Title: Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF) | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-001024-42 | Sponsor Protocol Number: GS-US-412-5624 | Start Date*: 2025-02-14 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for... | |||||||||||||
Medical condition: Healthy volunteers (Pre-exposure prophylaxis (PrEP) of human immunodeficiency virus 1 (HIV-1)) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005769-36 | Sponsor Protocol Number: GS-EU-177-0111 | Start Date*: 2009-01-15 | |||||||||||
Sponsor Name:Gilead Sciences Limited | |||||||||||||
Full Title: A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovi... | |||||||||||||
Medical condition: Antiretroviral-experienced HIV 1 infected subjects on their first and stable HAART regimen of efavirenz, emtricitabine, and tenofovir DF. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001385-11 | Sponsor Protocol Number: PrEP_COVID_19 | Start Date*: 2020-03-28 | |||||||||||
Sponsor Name:Plan Nacional Sobre SIDA | |||||||||||||
Full Title: Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled wit... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000180-13 | Sponsor Protocol Number: CLDT600A2409 | Start Date*: 2011-02-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: OPTIMA: A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Road... | |||||||||||||
Medical condition: Treatment in HBeAg-negative chronic hepatitis B patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) GR (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006158-16 | Sponsor Protocol Number: UMCN-AKF08.02 | Start Date*: 2009-02-13 | |||||||||||
Sponsor Name:Radboud university medical center | |||||||||||||
Full Title: Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) | |||||||||||||
Medical condition: HIV-infection in pregnant women | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004578-40 | Sponsor Protocol Number: SSAT066 | Start Date*: 2015-01-26 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal ... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000308-17 | Sponsor Protocol Number: GS-US-380-4030 | Start Date*: 2017-07-05 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir D... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002853-77 | Sponsor Protocol Number: TULIP | Start Date*: 2011-10-20 | |||||||||||
Sponsor Name:Fundació Lluita contra la SIDA | |||||||||||||
Full Title: PROSPECTIVE, RANDOMISED, CROSSOVER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE LIPID-LOWERING EFFECT OF ADDING TENOFOVIR/EMTRICITABINE CO-FORMULATION VS PLACEBO TO HIV-1-INFECTED SUBJECTS... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000727-85 | Sponsor Protocol Number: GS-US-104-0321 | Start Date*: 2015-02-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents | |||||||||||||
Medical condition: Human Immunodeficiency Virus-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001431-30 | Sponsor Protocol Number: M05-731 | Start Date*: 2005-07-30 |
Sponsor Name:Abbott GmbH & Co. KG | ||
Full Title: A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (... | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002017-30 | Sponsor Protocol Number: GS-US-283-1062 | Start Date*: 2016-03-14 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment ... | |||||||||||||
Medical condition: Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005078-37 | Sponsor Protocol Number: SOPHOCLES-P4G | Start Date*: 2017-05-26 | |||||||||||
Sponsor Name:Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases | |||||||||||||
Full Title: Public health targeting of PrEP at HIV positives’ bridging networks | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003921-27 | Sponsor Protocol Number: DORAGEN | Start Date*: 2019-06-25 |
Sponsor Name:Lluita contra la SIDA Foundation | ||
Full Title: Doravirine concentrations and antiviral activity in genital fluids in HIV-1 infected individuals. | ||
Medical condition: HIV infected individuals | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2017-002385-49 | Sponsor Protocol Number: IN-UK-311-3956 | Start Date*: 2017-11-27 | ||||||||||||||||
Sponsor Name:King's College Hospital NHS Foundation Trust | ||||||||||||||||||
Full Title: IN-UK-311-3956: A Feasibility Study of the Switch of Tenofovir disoproxil fumarate to Tenofovir alafenamide fumarate and the Effect on Glomerular Function in Chronic Hepatitis B and HIV co-infected... | ||||||||||||||||||
Medical condition: HIV and Hepatitis B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004935-30 | Sponsor Protocol Number: SP000336 | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:U.L.S.S. 9 DI TREVISO | |||||||||||||
Full Title: Study “before-after”: Adherence Evaluation to antiretroviral therapy administered in two different ways: - EPIVIR (3TC) + VIREAD (TDF) versus TRUVADA (FTC + TDF) - EPIVIR (3TC) + ZIAGEN (ABC) ... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023178-37 | Sponsor Protocol Number: GS-US-264-0106 | Start Date*: 2011-02-04 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (Type 1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002014-16 | Sponsor Protocol Number: VIR-MHB1-V200 | Start Date*: 2023-05-17 | |||||||||||
Sponsor Name:Vir Biotechnology, Inc. | |||||||||||||
Full Title: A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL) | |||||||||||||
Medical condition: Chronic Hepatitis B Virus (HBV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BG (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
